Chemotherapy or tyrosine kinase inhibitor for second line treatment in advanced non small cell lung cancer

被引：0
|
作者：
Jyoti, B. [1 ]
McKay, M. [1 ]
Wong, H. [1 ]
Alam, F. [1 ]
Eswar, C. [1 ]
Jain, P. [1 ]
Littler, J. A. H. [1 ]
Maguire, J. [1 ]
Schofield, C. P. [1 ]
Siva, A. [1 ]
Ramani, V. S. [1 ]
机构：
[1] Clatterbridge Ctr Oncol, Wirral, Merseyside, England
来源：
LUNG CANCER | 2012年 / 75卷
关键词：
D O I：
10.1016/S0169-5002(12)70019-3
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
18
引用
收藏
页码：S6 / S6
页数：1
相关论文
共 50 条
  • [1] Second-line treatment of non-small-cell lung cancer: chemotherapy or tyrosine kinase inhibitors?
    Passaro, Antonio
    Cortesi, Enrico
    de Marinis, Filippo
    EXPERT REVIEW OF ANTICANCER THERAPY, 2011, 11 (10) : 1587 - 1597
  • [2] Multiple-line Chemotherapy and Tyrosine Kinase Inhibitor Treatment in Patients with Advanced Lung Cancer
    Zhang, Hua
    Yang, Jie
    Deng, Yan-ming
    Zhao, Ning
    Liang, Jian-miao
    Yang, Shuang
    Zhang, Shun-da
    Feng, Wei-neng
    COMBINATORIAL CHEMISTRY & HIGH THROUGHPUT SCREENING, 2019, 22 (01) : 27 - 34
  • [3] Subsequent chemotherapy reverses acquired tyrosine kinase inhibitor resistance and restores response to tyrosine kinase inhibitor in advanced non-small-cell lung cancer
    Renhua Guo
    Xiaofen Chen
    Tongshan Wang
    Zhiyuan Zhang
    Jin Sun
    Yongqian Shu
    BMC Cancer, 11
  • [4] Subsequent chemotherapy reverses acquired tyrosine kinase inhibitor resistance and restores response to tyrosine kinase inhibitor in advanced non-small-cell lung cancer
    Guo, Renhua
    Chen, Xiaofen
    Wang, Tongshan
    Zhang, Zhiyuan
    Sun, Jin
    Shu, Yongqian
    BMC CANCER, 2011, 11
  • [5] CHEMOTHERAPY VERSUS ERLOTINIB IN THE SECOND LINE TREATMENT OF ADVANCED NON-SMALL CELL LUNG CANCER
    Fiala, Ondrej
    Pesek, Milos
    Krejci, Jana
    Sticha, Michal
    Minarik, Marek
    JOURNAL OF THORACIC ONCOLOGY, 2011, 6 (06) : S1259 - S1260
  • [6] Second-line chemotherapy in the treatment of advanced non-small cell lung cancer (NSCLC)
    Ardizzoni, A
    Tiseo, M
    JOURNAL OF CHEMOTHERAPY, 2004, 16 : 104 - 107
  • [7] Salvage surgery following tyrosine kinase inhibitor treatment for advanced non-small cell lung cancer
    Kobayashi, Masao
    Funaki, Soichiro
    Nagata, Hideki
    Furukawa, Mitsugi
    Morii, Eiichi
    Shintani, Yasushi
    SURGICAL CASE REPORTS, 2024, 10 (01):
  • [8] Second line chemotherapy (CT) in advanced non small cell lung cancer (NSCLC)
    Westeel, V
    Jacoulet, P
    Dubiez, A
    Polio, JC
    Pernet, D
    Depierre, A
    EUROPEAN JOURNAL OF CANCER, 1997, 33 : 1063 - 1063
  • [9] Meta-Analysis of EGFR Tyrosine Kinase Inhibitors Compared with Chemotherapy as Second-Line Treatment in Pretreated Advanced Non-Small Cell Lung Cancer
    Li, Ning
    Yang, Lu
    Ou, Wei
    Zhang, Liang
    Zhang, Song-liang
    Wang, Si-yu
    PLOS ONE, 2014, 9 (07):
  • [10] A SYSTEMATIC REVIEW OF TYROSINE KINASE INHIBITORS AS FIRST LINE TREATMENT FOR ADVANCED NON SMALL CELL LUNG CANCER
    Kamaruzaman, H. F.
    Abd Rahim, Ku K. N.
    Lee, S. W.
    Darus, Mohd N.
    Sabirin, J.
    VALUE IN HEALTH, 2016, 19 (07) : A885 - A885
12345